Aclaris Therapeutics (ACRS) Receivables (2017 - 2025)
Aclaris Therapeutics' (ACRS) quarterly Receivables came in at $194000.0 in Q2 2025, down 72.29% year-on-year from $700000.0 in Q2 2024, and down 22.4% quarter-over-quarter from $250000.0 in Q1 2025.
Aclaris Therapeutics (ACRS) Receivables (2017 - 2025) Analysis & Trends
Aclaris Therapeutics' Receivables history runs 9 years deep, the most recent figure standing at $194000.0 for Q2 2025.
- On a quarterly basis, Receivables fell 72.29% year-over-year to $194000.0 in Q2 2025; TTM through Jun 2025 was $194000.0, a 72.29% decrease from a year earlier, with the FY2024 full-year figure at $318000.0, up 6.71% from the prior year.
- Receivables eased to $194000.0 in Q2 2025 per ACRS's latest filing, from $250000.0 in the prior quarter.
- Across five years, Receivables topped out at $963000.0 in Q2 2021 and bottomed at $194000.0 in Q2 2025.
- The 5-year median for Receivables is $540500.0 (2022), against an average of $531777.8.
- Across the five-year window, Receivables jumped 62.41% in 2024 and sank 72.29% in 2025, its largest moves.
- Year by year, Receivables stood at $647000.0 in 2021, then declined by 25.19% to $484000.0 in 2022, then tumbled by 38.43% to $298000.0 in 2023, then advanced by 6.71% to $318000.0 in 2024, then plunged by 38.99% to $194000.0 in 2025.
- Per Business Quant, the three latest ACRS Receivables figures stand at $194000.0 (Q2 2025), $250000.0 (Q1 2025), and $318000.0 (Q4 2024).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 4.97 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 938.02 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 1.13 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 2.00 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 5.73 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.93 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Aclaris Therapeutics | 705.88 Mn | 705.88 Mn | 1.60 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 194,000.00 |
| Mar 31, 2025 | 250,000.00 |
| Dec 31, 2024 | 318,000.00 |
| Sep 30, 2024 | 343,000.00 |
| Jun 30, 2024 | 700,000.00 |
| Mar 31, 2024 | 373,000.00 |
| Dec 31, 2023 | 298,000.00 |
| Sep 30, 2023 | 346,000.00 |
| Jun 30, 2023 | 431,000.00 |
| Mar 31, 2023 | 686,000.00 |
| Dec 31, 2022 | 484,000.00 |
| Sep 30, 2022 | 597,000.00 |
| Jun 30, 2022 | 637,000.00 |
| Mar 31, 2022 | 633,000.00 |
| Dec 31, 2021 | 647,000.00 |
| Sep 30, 2021 | 835,000.00 |
| Jun 30, 2021 | 963,000.00 |
| Mar 31, 2021 | 837,000.00 |
| Dec 31, 2020 | 1.07 Mn |
| Sep 30, 2020 | 1.19 Mn |